biotech
<a href="https://www.fiercebiotech.com/biotech/entradas-stock-craters-dmd-data-underperform-expectations-handing-advantage-novartis" hreflang="en">Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis</a>
FierceBiotech
May 11, 2026 · 21s listen
Listen · FierceBiotech
<a href="https://www.fiercebiotech.com/biotech/entradas-stock-craters-dmd-data-underperform-expectations-handing-advantage-novartis" hreflang="en">Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis</a>
0:00-0:21
Live · Kokoro-82M
Audio pre-rendered by Storyflo · cached + delivered from the edge
Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout from a key readout expected to validate its platform.
Share
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to FierceBiotech.
Heard via Storyflo
Get audio versions of every article you read.
Pick what matters — your audio curator gets you into your daily flo.